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Key Points: Mutations causing quantitative types 1 and 3 von Willebrand disease are seen 
throughout VWF, but those causing qualitative type 2 affect discrete functional domains. 
Genetic analysis can aid determination of VWD type and thus relevant treatment when phenotypic 
analysis is inconclusive. 
Learning Objectives: VWD displays a wide range of different phenotypes resulting from mutation to 
its several different domains. 
VWD inheritance pattern can be dominant, co-dominant or recessive dependent on the contribution 
of different mutations to phenotype. 
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Abstract  
Investigation of a patient with possible von Willebrand disease includes a range of phenotypic 
analyses. Often, this is sufficient to discern disease type, and this will suggest relevant treatment. 
,ŽǁĞǀĞƌĨŽƌƐŽŵĞƉĂƚŝĞŶƚƐ ?ƉŚĞŶŽƚǇƉŝĐĂŶĂůǇƐŝƐĚŽĞƐŶŽƚƐƵĨĨŝĐŝĞŶƚůǇĞǆƉůĂŝŶƚŚĞƉĂƚŝĞŶƚ ?ƐĚŝƐŽƌĚĞƌ
and for this group, genetic analysis can aid diagnosis of disease type. PCR and Sanger sequencing 
have been mainstays of genetic analysis for several years. More recently, next generation 
sequencing has become available, with the advantage that several genes can be simultaneously 
analysed where necessary, e.g. for discrimination of possible type 2N von Willebrand disease or mild 
haemophilia A. Additionally, several techniques can now identify deletions/duplications of an exon 
or more that result in von Willebrand disease including multiplex ligation-dependent probe 
amplification and micro-array analysis. Algorithms based on next generation sequencing data can 
also identify missing or duplicated regions. These newer techniques enable causative VWF defects to 
be identified in more patients than previously, aiding a specific VWD diagnosis. Genetic analysis can 
also be helpful in the discrimination between type 2B and platelet-type von Willebrand disease and 
in prenatal diagnosis for families with type 3. 
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Introduction 
von Willebrand disease (VWD) is the most commonly diagnosed autosomally inherited bleeding 
disorder. It affects approximately one in 10,000 individuals sufficiently to be referred to a tertiary 
care centre.
1
 von Willebrand factor (VWF) is a very large multimeric glycoprotein
2
 that performs two 
essential haemostatic functions; it provides a means to bind platelets at sites of vascular damage 
and at high shear stress supports platelet aggregation. It also carries and protects coagulation factor 
VIII (FVIII) in the circulation, delivering it to sites of vascular injury. 
Initial analysis for possible VWD examines bleeding symptoms in the patient and their family and this 
typically includes epistaxis, easy bruising and other haemorrhagic symptoms. A bleeding score (BS) 
system has been defined and can help predict outcomes and replacement therapy.
3
 Laboratory 
testing of quantity and activity parameters for VWF then determine whether they deviate from the 
normal range. VWD is divided into three main categories; type 1 VWD (VWD1) is a partial 
quantitative deficiency, and VWD3 an almost complete quantitative deficiency of VWF whilst VWD2 
is categorised into 4 types; 2A, 2B, 2M and 2N dependent on VWF function perturbed by mutation. 
Recently, guidelines on the diagnosis and management of VWD have recommended that cut-off 
values are used in the diagnostic pathway. These suggest that patients having VWF activity levels 
A? ? ?-35 /h ?Ě>ƐŚŽƵůĚďĞĐůĂƐƐŝĨŝĞĚĂƐŚĂǀŝŶŐ ?ůŽǁst& ?ŝŶƌĞĐŽŐŶŝƚŝŽŶƚŚĂƚƚŚŝƐĐĂŶďĞĂƌŝƐŬĨĂĐƚŽƌĨŽƌ
bleeding, rather than being given a VWD diagnosis.
4,5
  
For many patients diagnosed with VWD, laboratory phenotypic assays readily suggest VWD type in 
the individual, enabling the clinical team to select the most relevant management for that disease 
type. However, where this is not the case, genetic analysis can help understand the paƚŝĞŶƚ ?Ɛ
disorder through identification of the causative mutation(s). For many years, PCR and Sanger 
sequencing were utilised to identify mutations in the VWF gene (VWF), but more recently, next 
generation sequencing (NGS) has been introduced to diagnostic and research institutions. This 
technology enables simultaneous parallel sequencing of many genes. Large deletions and 
duplications of an exon or more can be sought using multiplex ligation-dependent probe 
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amplification (MLPA) or microarray specific for VWF, or through analysis of NGS data using an 
algorithm to seek missing or duplicated regions.  
This article summarises the mutation classes and their inheritance patterns associated with the 
different VWD types and how this information can be useful in provision of the most relevant 
patient management. 
 
Type 1 VWD 
This is the most prevalent VWD type in most populations, with proportions of patients up to 70% in 
some studies. Type 1 VWD (VWD1) patients have von Willebrand factor antigen (VWF:Ag) and VWF 
activity assays with activity/antigen ratio >0.7 and normal VWF multimers. VWF activity can be 
determined using ristocetin co-factor (VWF:RCo), that measures binding to GpIb, whilst VWF:CB 
measures binding to collagen. New assays assess binding to engineered GpIb fragments genetic 
(VWF activity).
6
 Recent recommendations of using lower cut-off values for inclusion of these patients 
amongst those with VWD (30 or 35 IU/dL) will reduce the proportion of individuals classified as 
affected by VWD1.
7,8
 For those within this borderline group, strongest predictors of VWD diagnosis 
are reduced VWF:RCo in platelet aggregation , especially in those with non-O blood-group and 
female sex.
9
  
Mutations are located throughout VWF from the promoter region
10
 to exon 52,
11,12
 the majority are 
missense mutations (75%), while splice, deletion, nonsense, insertion, duplication and large in-frame 
deletions mutations comprise minor proportions.
13
 Most patients have dominantly inherited disease 
resulting from a single mutation whilst a smaller proportion (~5-10%) have more than one mutation 
contributing to their symptoms, some with recessive inheritance.
14-16
 Blood-group O is present in up 
to ~65% of VWD1.
11
 
The predominant mechanism responsible is intracellular retention of mutant VWF, resulting in 
reduced secretion into plasma.
17
 Rapid VWF clearance from the circulation also contributes,
18
 with 
VWF half-life in unaffected individuals being approximately 8-12 hours and individuals with ABO 
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blood group O having shorter half-lives. The ratio between VWF propeptide (VWFpp) and VWF:Ag 
ĐĂŶďĞĞǆƉůŽŝƚĞĚƚŽŚŝŐŚůŝŐŚƚƌĂƉŝĚĐůĞĂƌĂŶĐĞ ?ǁŝƚŚƚŚĞ ?sŝĐĞŶǌĂ ?ŵƵƚĂƚŝŽŶƉ ?ƌŐ ? ? ? ?,ŝƐ
exemplifying this phenotype. The VWF half-life following desmopressin administration was ~10% 
that of Haemate P. Modelling mathematically the synthesis, clearance and cleavage of p.Arg1205His 
using a one tenth half-life relative to normal VWF replicated the mutation features of low VWF level, 
ultralarge multimers and reduced satellite bands.
19
 Rapid clearance can result in desmopressin not 
providing sufficiently sustained VWF elevation for longer clinical procedures; VWFpp/VWF:Ag 
measurement or genetic analysis can identify the cause.  
In contrast to VWD types 2A, 2B and 2M where most heterozygous mutations are fully penetrant (all 
individuals with the mutation have disease symptoms), approximately half of VWD1 families have 
incomplete penetrance (only some individuals with a mutation have symptoms). ABO blood group 
contributes to reduced VWF:Ag level and this is exemplified by the common variant p.Tyr1584Cys.
20
  
The main use for genetic analysis in VWD1 is to help understand the cause of the more severe 
presentations and inheritance risk for family members. 
 
Other genes that contribute to variation in VWF level 
The Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) Consortium combined 
analysis of 5 community-based studies (23,608 participants with European ancestry) to seek 
genome-wide single nucleotide variant associations with F7, F8 and VWF genes. In addition to VWF 
and ABO, variants in 5 further genes were identified that influenced both VWF and FVIII levels; 
STXBP5, SCARA5, STAB2, TC2N and CLEC4M. Type 1, but not type 2 patient analysis in the Willebrand 
in Netherlands study demonstrated association of STXBP5 with VWF:Ag level reduction of -3.0 IU/dL 
per allele and CLEC4M with VWF:Ag level of -4.3 IU/dL and VWF activity of -5.75 IU/dL per allele.
21
 
ABO blood group is associated with up to ~25% variation in VWF levels between blood-group O and 
non-O. 
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Type 2 VWD 
Type 2A VWD 
This is the largest grouping amongst VWD2, and includes several different disease mechanisms 
resulting from mutations in diverse VWF domains (Figure 1). All have high molecular weight 
multimer (HMWM) loss, but demonstrate differing multimer profiles.
22
 Most patients have reduced 
VWF activity/VWF:Ag ratios. A tertiary category for VWD2A includes mutations in the most common 
locations; the A2 domain (IIA), D3 domain (IIE), D2 domain (IIC) and CK domains (IID).
23
  
  
VWD2A/IIA  
Classic VWD2A/IIA mutations are located in the A2 domain (amino acids (AA) 1500-1672) and 
comprise half of 2A mutations listed on the VWF database.
24
 Mutation mechanisms include impaired 
VWF secretion and enhanced sensitivity to the cleaving protease, ADAMTS13 that occurs under high 
shear stress.
25
 
 
A1 domain 
20% of VWD2A mutations lie in the adjacent A1 domain (AA 1271-1458) where they impact binding 
to glycoprotein IB (GPIb) and include the common variants p.Arg1315Cys, p.Arg1374Cys and 
p.Arg1374His. These mutations have been variously classified as resulting in VWD types 2A, 2M, and 
1 as multimer abnormalities do not always appear to be detectable.
26,27
 
 
D3 domain   
The VWD2A/IIE phenotype was described many years ago, but mutations responsible were only 
described as a single VWD category in 2010.
28
 Mutations result in intracellular retention, relative loss 
of HWMW and reduced ADAMTS13-mediated proteolysis. Missense mutations are located in ex22 
and 25-28, many introducing/substituting cysteine residues; replacement of p.Cys1130 is the most 
common change.
29
 These mutations, like p.Arg1205His result in rapid VWF clearance.  
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D2 domain 
VWD2A/IIC propeptide mutations have a multimerisation defect resulting in reduced HMWM. Unlike 
most VWD2A, mutations are recessively inherited and are located in ex11-16 (AA 404-768). In 
addition to homozygous missense mutations, patients also have small in-frame deletions/insertions 
with some being compound heterozygous.  
 
CK domain 
VWD2A/IID mutations are located in the cysteine knot domain and affect ex51-52 (AA 2730-2801). 
Mutations impair VWF dimerisation leading to odd numbered satellite bands on multimer analysis.
30
 
 
Mutation analysis can aid understanding of disease process in VWD2A either through analysis of 
exon 28 alone or preferably of the entire gene. 
 
Type 2B VWD  
VWD2B results from an unusual gain-of-function mutation type.
31
 Dominantly inherited A1 domain 
missense mutations (AA 1266-1461) alter VWF confirmation, facilitating spontaneous interaction 
with GPIb. This can result in circulating aggregates of VWF-platelets that are cleared from the 
circulation, resulting in thrombocytopenia. Platelet-type VWD (PT-VWD) results from dominantly 
inherited gain-of-function missense mutations in GP1BA, leading to a similar phenotype.
32
 Treatment 
may differ between these two disorders; platelet transfusions can result in platelet clearance in 
VWD2B,
33
 where they may be helpful in PT-VWD. Genetic analysis is straightforward for these 
disorders, often using Sanger sequencing to examine the VWF A1 domain and GP1BA region 
encoding the beta hairpin loop (AA 246-255).
34
  
 
Type 2M VWD 
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Type 2M mutations reduce VWF-GPIb or VWF-collagen binding to sub-endothelium, with no HMWM 
loss. There is often a marked difference between VWF activity and VWF:Ag, with activity 
considerably lower than VWF:Ag. The A1 domain is the predominant mutation location (exon 28, AA 
1229-1439), where missense mutations impair GPIb interaction, reducing platelet activation. 
Mutations affecting collagen-binding are not always sought through phenotypic analysis; they may 
impair binding to the more commonly used collagen types I/III or the less commonly investigated 
types IV/VI.
35-37
 These mutations are located in the A1 or A3 domains (ex28-32).
24
 
 
Type 2N VWD 
st ?EŵŝƐƐĞŶƐĞŵƵƚĂƚŝŽŶƐŝŶƚŚĞ ?-D3 domains (ex17-25) impair binding of FVIII to VWF 
(VWF:FVIIIB), resulting in reduced FVIII half-life in the circulation.
38
 Typically, FVIII:C levels mimic 
those seen in mild haemophilia A (range 5-40 IU/dL), whilst VWF:Ag levels are normal or mildly 
reduced.
38
 Inheritance is recessive; at least one of the two mutations affects VWF:FVIIIB. The second 
mutation can be a further copy of the same missense mutation, a different VWF:FVIIIB missense 
mutation or commonly a null allele (nonsense, splice-site, deletion/insertion). The most frequent 
mutation in the European populations is p.Arg854Gln, for which ~1% individuals are heterozygous. 
Unless there is an obvious family history indicating inheritance pattern, it can be difficult to 
distinguish mild haemophilia A from 2N VWD. A phenotypic VWF:FVIIIB assay or genetic analysis to 
discriminate these two disorders can be used. Desmopressin response may be curtailed in 2N 
patients due to shortened FVIII half-life. 
 
Type 3 VWD 
In populations where consanguineous partnerships are common, the prevalence of VWD3 may be 
10-20 fold greater than in outbred populations. In European populations, ~one individual/10
6 
is 
affected. Patients have undetectable VWF levels (<5 IU/dL) and reduced FVIII (<10 IU/dL) resulting 
from lack of VWF to protect FVIII from proteolysis. 15-20% of mutations are missense substitutions 
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and these can result in a less severe phenotype, with reduced VWFpp/VWF:Ag indicating enhanced 
clearance from plasma, and reduced BS compared with patients having two null mutations. 
Missense mutations often result in VWF being retained within the endoplasmic reticulum as VWF is 
likely misfolded. Whereas VWD3 patients with null alleles in the Willebrand in the Netherlands (WiN) 
study produced no detectable VWF, those with measurable VWFpp (indicating some VWF 
production) demonstrated higher VWF:Ag (0 v 4 IU/dL), activity (0 v 1 IU/dL) and FVIII levels (2 v 9 
IU/dL).
18
 The disorder is recessively inherited with most patients having two null alleles. A very small 
proportion may develop anti-VWF antibodies, with only a rare patient where the antibody is 
inhibitory for one of the VWF activities. Genetic analysis can identify causative mutation(s) in nearly 
all VWD3 affected individual so that inheritance risks in relatives can be determined. Prenatal 
diagnosis for a possible VWD3 affected pregnancy can be undertaken using chorionic villus or 
amniocentesis samples from ~11-18 weeks gestation, dependent on sample type. 
Heterozygous carriers of a null mutation may have normal or reduced VWF plasma levels. From 15-
48% have been diagnosed with st ?ƚŚĂƚĐĂŶďĞĐůĂƐƐŝĨŝĞĚĂƐŚĂǀŝŶŐ ?ĐŽ-ĚŽŵŝŶĂŶƚŝŶŚĞƌŝƚĂŶĐĞ ? ?39,40 
 
Clinical utility of VWF genetic testing 
Molecular testing for VWD is justified in individuals in whom phenotypic assays suggest VWD, but 
genetic analysis may provide a more specific diagnosis to aid appropriate management. Examples 
are; to distinguish between VWD2N, mild hemophilia A in males, or symptomatic hemophilia carrier 
status in females; to discriminate between VWD2B and platelet-type pseudo VWD (PT-VWD),  to 
ŚĞůƉƵŶĚĞƌƐƚĂŶĚƚŚĞƉĂƚŝĞŶƚ ?ƐĚŝƐŽƌĚĞƌǁŚĞƌĞŵŽƌĞƚŚĂŶŽŶĞŵƵƚĂƚŝŽŶůĞĂĚƐƚŽĂŵŽƌĞĐŽŵƉůĞǆ
phenotype and to provide prenatal diagnosis for families with VWD3. For VWD1, patients where 
rapid VWF clearance occurs following desmopressin administration or when inheritance pattern is 
unclear and mutation determination can explain disease risk in relatives, genetic analysis can be 
useful. 
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Conclusion 
VWF mutations are located throughout the VWF gene, resulting in a wide range of mutation types 
that include quantitative and qualitative disorders. VWF protein is involved in several processes that 
can be damaged by mutation and the varying phenotypes in VWD illustrate the processes impaired. 
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Table 1. Summary of mutation location for VWD patients reported on the VWF mutation database 
VWD 
Type 
VWF 
domain 
Mutation 
location 
Inheritance pattern Phenotype 
1 All Promoter-ex52 Majority dominant, minority >1 mutation or recessive VWF activity/VWF:Ag >0.7 
2A/IIC D2 Ex11-16 Recessive Mostly very discrepant VWF activity/VWF:Ag 
2A/IIE D3 Ex22 & 25-28 Dominant Discrepant VWF activity/VWF:Ag, most <0.6 
2A A1 Ex28 Dominant Discrepant VWF activity/VWF:Ag 
2A/IIA A2 Ex28 Dominant Discrepant VWF activity/VWF:Ag 
2A/IID CK Ex51-52 Dominant Discrepant VWF activity/VWF:Ag 
2B A1 Ex28 Dominant Wide range of VWF activity/VWF:Ag possible 
2M A1 
A3 
Ex28 
Ex29-32 
Dominant 
 
Discrepant VWF activity/VWF:Ag and/or 
VWF:CB/VWF:Ag 
2N  ?-D3 Ex17-20 
Ex24-25 
Recessive FVIII:C 5-40 IU/dL 
VWF:Ag normal/reduced 
3 All  ? ?st&-Ex52 Recessive VWF:Ag <5 IU/dL 
FVIII:C <10 IU/dL 
 
VWF mutation database - https://grenada.lumc.nl/LOVD2/VWF/variants.php 
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Figure 1. Structure of von Willebrand factor, highlighting mutation location 
 
 
 
 
 
 
 
 
 
 
 
 
Exons encoding specific VWF domains are highlighted above the VWF domain structure. Shaded rectangles indicate VWF domains. Mutation locations are 
denoted by shaded bars indicating regions associated with each VWD type. Furin (light grey) and ADAMTS13 cleavage sites (dark grey) are indicated by 
arrows. 
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